Ambit's powerful profiling technology, innovative licensing strategy, history of kinase expertise and pipeline of cancer therapeutics are making news.

12.18.09

Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications

12.11.09

Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia

Our proprietary kinase profiling platform, KINOMEscan, turns the promiscuity of kinase inhibitors into a key discovery and development advantage.
More Info »

Click here for downloadable KINOMEscan Fact Sheet

Our lead compound AC220, a small molecule kinase inhibitor for the treatment of Acute Myeloid Leukemia, entered the clinic in 2006.

From profiling services to clinical development expertise, find out what Ambit has to offer.

More Info »